Reaction
Prerenal Failure reporting signals
As of the last recalculation, Prerenal Failure appears in 1,378 FAERS reports alongside 31 co-occurring drug terms. The strongest observed disproportionality signal is TOLVAPTAN (PRR 21.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tolvaptan | 20 | 21.1 | 21.1 |
| Febuxostat Tablets 40 Mg | 13 | 19.5 | 19.5 |
| Febuxostat Tablets 80 Mg | 13 | 19.5 | 19.5 |
| Ipilimumab | 35 | 12.5 | 12.6 |
| Sulfasalazine | 59 | 11.9 | 11.9 |
| Febuxostat | 13 | 11.8 | 11.8 |
| Dapagliflozin | 24 | 11.7 | 11.7 |
| Leflunomide | 70 | 10.6 | 10.6 |
| Regorafenib | 8 | 10.5 | 10.5 |
| Pitavastatin Calcium | 7 | 10.4 | 10.4 |
| Empagliflozin | 43 | 9.9 | 9.9 |
| Tocilizumab | 71 | 9.9 | 9.9 |
| Olmesartan Medoxomil | 22 | 9.4 | 9.4 |
| Certolizumab Pegol | 67 | 9.0 | 9.0 |
| Granisetron Hydrochloride | 6 | 8.7 | 8.7 |
| Granisetron | 6 | 8.7 | 8.7 |
| Nivolumab | 51 | 8.2 | 8.2 |
| Pemetrexed | 11 | 7.8 | 7.8 |
| Pembrolizumab | 50 | 7.4 | 7.4 |
| Pemetrexed Disodium | 18 | 7.2 | 7.2 |
| Selinexor | 4 | 7.0 | 7.0 |
| Axitinib | 8 | 6.2 | 6.2 |
| Encorafenib | 4 | 6.1 | 6.1 |
| Durvalumab | 8 | 6.0 | 6.0 |
| Dabrafenib | 8 | 5.8 | 5.8 |
| Lenvatinib | 12 | 5.6 | 5.6 |
| Tofacitinib | 64 | 5.4 | 5.4 |
| Carfilzomib | 10 | 5.4 | 5.4 |
| Alpelisib | 3 | 5.2 | 5.2 |
| Vemurafenib | 4 | 5.0 | 5.0 |
| Cetuximab | 10 | 4.8 | 4.8 |